News

Genticel bags €18.2m
Enlarge image

BusinessFranceGermany

Genticel bags €18.2m

26.04.2013 - French vaccine specialist Genticel SA (Toulouse) has raised €18.2m in a financing round.

The round was led by Wellington Partners (Munich), which included all current institutional investors  such as IDInvest Partners, Edmond de Rothschild Investment Partners (Paris), InnoBio fund, IRDI and Amundi Private Equity Funds.   The company said it will use the new funds to push its two therapeutic vaccine candidates against the cancer-causing human papilloma virus subtypes HPV16 and HPV18.

Its ProCervix vaccine, which is built on Genticel’s CyaA antigen delivery technology, has successfully finished phase I clinical study. The phase I trial (n=47) revealed no dose limiting toxicity and no patient drop-out. In addition, ProCervix induced a dose-dependent immune response as well as viral clearance in a substantially larger percentage of patients as compared to placebo. ProCervix will enter into phase II development in order to demonstrate proof of efficacy. Genticel’s other pipeline product is a CyaA-based multivalent HPV vaccine with additional virus subtype coverage.    Currently, there is preventive HPV vaccination but still no effective treatment against established infection with high-risk HPV types albeit promising approaches.

Genticel’s vaccines are designed for the treatment of infected women who have not yet developed high-grade cervical lesions or cancer.    Recent estimates by the World Health Organization suggest that world-wide approximately 300 million women are carriers of HPV infection at any given time and approximately 500,000 patients are diagnosed with cervical cancer each year.

© eurobiotechnews.eu/tg

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M and AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

M and ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

MandAFranceGermany

03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.

FinanceBelgium

01.07.2014 Belgian antibody specialist Ablynx has raised €41.7m through a private placement of new shares and plans on boosting their range of nanobodies in development.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CHRONTECH PHARMA (S)0.08 SEK14.29%
  • PROTHENA PLC (IE)18.44 USD6.84%
  • WILEX (D)3.28 EUR5.47%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • HYBRIGENICS (F)1.71 EUR-8.56%

TOP

  • WILEX (D)3.28 EUR349.3%
  • SANTHERA (CH)69.50 CHF114.8%
  • ADDEX (CH)4.21 CHF92.2%

FLOP

  • MERCK KGAA (D)63.45 EUR-51.0%
  • THROMBOGENICS (B)8.55 EUR-47.3%
  • VERONA PHARMA (UK)1.12 GBP-46.2%

TOP

  • SANTHERA (CH)69.50 CHF3410.1%
  • GW PHARMACEUTICALS (UK)415.25 GBP756.2%
  • SKYEPHARMA PLC (UK)260.00 GBP314.3%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.2%
  • CYTOS (CH)0.27 CHF-92.1%
  • THROMBOGENICS (B)8.55 EUR-72.5%

No liability assumed, Date: 21.07.2014